DNLI   $30.91  -0.45% Market Closed After Close 30.91 0.0

Denali Therapeutics Inc
Total Cash 896.04M
totalCashPerShare 6.259
EBITDA -494.61M
Total Debt 48.75M
quickRatio 12.041
currentRatio 12.456
Total Revenue 1.27M
debtToEquity 3.515
Revenue/Share 0.009
ROA -0.22042
ROE -0.32609
grossProfits
freeCashflow -208.85M
operatingCashflow -390.86M
earningsGrowth
revenueGrowth
grossMargins 0.0
ebitdaMargins 0.0
operatingMargins -390.85397
profitMargins 0.0
enterpriseValue 3.56B
forwardPE -11.26679
floatShares 123.73M
sharesOutstanding 143.16M
sharesShort 9.01M
sharesShortPriorMonth 7.19M
dateShortInterest
sharesPercentSharesOut 0.06%
heldPercentInsiders 0.14%
heldPercentInstitutions 0.90%
Short Ratio help_outline 10.47%
shortPercentOfFloat 0.07%
impliedSharesOutstanding
bookValue 9.691
Price To Book help_outline 3.12
earningsQuarterlyGrowth
netIncomeToCommon -419.65M
trailingEps -2.86%
forwardEps -2.68%
enterpriseToEbitda -7.19
lastDividendValue
lastDividendDate
currentQuarterEstimate -0.61 3Q 2024
institutionsCount 306
lastUpdated Sept. 16, 2024, 4:42 p.m.